SOLICITATION NOTICE
65 -- Procurement of TET (tetracycline)-negative premium grade fetal bovine serum (FBS) for Identifying new molecular targets for therapy in B Cell lymphoma
- Notice Date
- 12/1/2016
- Notice Type
- Presolicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC72506-76
- Archive Date
- 12/13/2016
- Point of Contact
- Catherine Muir, Phone: (240) 276-5434
- E-Mail Address
-
muirca@mail.nih.gov
(muirca@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, UNITED STATES Description: National Cancer Institute (NCI), Center for Cancer Research (CCR), Lymphoid Malignancies Branch, plans to procure on a sole source basis the services for the procurement of TET (tetracycline)-negative premium grade fetal bovine serum (FBS) from VWR International; 100 Matsonford Road, Radnor, PA 19087-8660. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1), and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 325414 and the business size standard is 1,250 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price, type contract. Delivery will be within 90 days from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. The Lymphoid Malignancies Branch, NCI, CCR, since its inception in 1956, (formerly the Metabolism Branch) has been an exemplar of translational research. Its investigators combine basic research, preclinical investigation, and drug development with innovative, therapeutic clinical trials that have as their scientific basis fundamental research performed in the Branch. Primary interests of the Branch concern the identification of abnormalities to the regulation of the immune response and the definition of molecular disorders that underlie lymphoid malignancies. The fundamental laboratory-based studies concern molecular biology of human lymphoid malignancies uses genomic approaches to establish a molecular diagnosis of lymphoid malignancies and to discover new targets for therapy of these diseases. The Lymphoid Malignancies Branch studies the molecular mechanisms of B cell lymphomagenesis with the goal of identifying new molecular targets for therapy. A critical part of this effort is the growth of cell line models of various lymphomas in tissue culture. This requires TET (tetracycline)-negative premium grade fetal bovine serum (FBS). Contractor shall provide the following: Quantity of (120), 500mL each of TET (tetracycline)-negative premium grade fetal bovine serum (FBS). Payment shall be made upon receipt and acceptance of the specified product. Payment authorization requires submission and approval of a progress report and an invoice per the Invoice & Payment Provisions in the Purchase Order. This laboratory requirement is provided by VWR International. The proposed formulation of TET-negative premium grade fetal bovine serum lot #231B15 is an essential, consistent component of all clinical research projects performed in the Lymphoid Malignancies Branch. There is no other known serum that can match the needed technical quality and utility of the proposed TET-negative premium grade fetal bovine serum. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 10:00AM EST, on Dec. 12, 2016. All responses and questions must be in writing and faxed (240) 276-5401 or emailed to Catherine Muir, Contracting Officer via electronic mail at muirca@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference: N02RC72506-76 on all correspondence
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC72506-76/listing.html)
- Record
- SN04339890-W 20161203/161201233848-68fdb519f28be8be8ac30ad53f28dcff (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |